Property:Has abstract
From Bioblast
This is a property of type Text.
2
2016 Spring PaduaMuscleDays: Muscle Decline in Aging and Neuromuscular Disorders - Mechanisms and Countermeasures, Padua, IT +
2020 PaduaMuscleDays - 30 years of translational research, Vitual Event, 2020 +
24th Kalorimetrietage, Braunschweig, Germany, 2021. +
25<sup>th</sup> Krakow Conference on Endothelium, Krakow, Poland. +
28th Congress of the Polish Physiological Society, Virtual, 2021 +
2nd International Munich ROS Meeting, Munich, Germany, 2018 +
2nd Mitochondria Conference, Lisbon, Portugal, 2023. +
<br/>
'''Oroboros distributor training'''. Innsbruck, Austria; 2023 Nov 07-09. +
'''2nd Workshop on Mitochondrial Functional Diagnostics - Diagnostic database''' Innsbruck, Austria, 2023 +
3
36th annual international congress of Czech Nutrition Society, Hradec Kralove, Czech Republic, 2020 +
37th Annual Meeting of the ISHR-ES, Porto, Portugal, 2023 +
'Mitochondria, Metabolism and Energetics': [[Media:MiPNet18.14 IOC85 Mahabaleshwar.pdf|'''38th Mahabaleshwar Seminar''']], [http://www.tifr.res.in/~dbsconf/mito2014/Home.html mito2014], including '''[[MiPNet18.14 | 85th OROBOROS O2k-Workshop]]'''. +
4
46th annual congres of the International Society of Oncology and Biomarkers, Athens, Greece, 2019 +
The 4th China Symposium on Neuro-Controlled Metabolism, Hangzhou city, China, 2021 +
4th Global Chinese Symposium & The 8th Symposium for Cross-straits on Free Radical Biology and Medicine 2018 Macao CN +
4th Global Chinese Symposium & The 8th Symposium for Cross-straits, Hong Kong and Macao on Free Radical Biology and Medicine, Macao, China, 2018 +
4th edition Metabolism & Cancer, Virtual, 2021
== Program ==
:::: [https://www.metabolism-cancer.com/program/ here]
== Organizers ==
:::: The list of organizers can be found [https://www.metabolism-cancer.com/under-construction/ here]
== Registration ==
:::: [https://www.metabolism-cancer.com/registration/ Registration and more information]
== Oroboros at MetaboCancer 2021==
:::: [[Gnaiger Erich]]: Oroboros Instruments innovations - NextGen-O2k and Bioenergetics Communications, ''May 28th at 11:25''
=== Booth ===
:::: The Oroboros team is looking forward to welcome you at our Oroboros booth which will be available at this conference.
== Support ==
[[File:Template NextGen-O2k.jpg|right|350px|link=NextGen-O2k]]
[[Category:NextGen-O2k]]
:::: Supported by project NextGen-O2k which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 859770.
<br/>
<br/>
<br/>
<br/> +
5
5th Academic Symposium of Metabolic Biology Branch of Chinese Biophysical Society, Zunyi, China, 2022 +
5th International Mitochondrial Medicine Conference Mitochondrial, Online, 2021 +
5th edition Metabolism & Cancer, Nice, France, 2023
== Venue ==
:::: [https://www.metabolism-cancer.com/?utm_source=altemail&utm_medium=email&utm_campaign=2023-01-04%20METABO%202023%201 How to get there]
== Program ==
:::: Program available [https://www.metabolism-cancer.com/?utm_source=altemail&utm_medium=email&utm_campaign=2023-01-04%20METABO%202023%201 here]
== Organizers ==
:::: The list of organizers can be found [https://www.metabolism-cancer.com/?utm_source=altemail&utm_medium=email&utm_campaign=2023-01-04%20METABO%202023%201 here]
== Registration ==
:::: [https://www.metabolism-cancer.com/?utm_source=altemail&utm_medium=email&utm_campaign=2023-01-04%20METABO%202023%201 Registration and more information] +
6
6th Annual Conference of Chinese Society for Neurobiological Control of Metabolism 2024 Quanzhou CN +
6<sup>th</sup> Annual Conference of Chinese Society for Neurobiological Control of Metabolism, Quanzhou, China, 2024 +
6th Biannual Meeting on Mitochondria Apoptosis & Cancer, Prague, Czech Republic, 2019 +
6th EU-Cardioprotection WG Meeting CA16625 on mito and metabolism as targets for cardioprotection., Virtual Event, 2021 +
6th International Conference on Tumor Microenvironment and Cellular Stress: Signaling, Metabolism, Imaging and Therapeutic Targets, Chania, Crete, Greece, 2019 +
6th Research Day, Innsbruck, Austria, 2023 +
7
77th Annual Meeting of the Japanese Cancer Association at the Osaka International Convention Center and RIHGA, Osaka, Japan, 2018 +
7th European Phycological Congress, Zagreb, Croatia, 2019 +
7th Molecular Mechanisms of Axon Degeneration Meeting, Loch Lomond, Scotland, Great Britain, 2019 +
7th World Congress on Targeting Microbiota, Krakow, Poland, 2019
== Venue ==
:::: Park Inn by Radisson Krakow Hotel
:::: Ul. Monte Cassino 2 PL
:::: 30337 - Krakow - Poland
:::: [https://www.microbiota-site.com/venue.html More information]
== Organizer ==
:::: [https://www.microbiota-site.com/committee.html Information available here]
== Programme ==
:::: [https://www.microbiota-site.com/images/2019/PDF/Targeting_Microbiota_2019_Agenda_-_V7.pdf Agenda]
== Speakers ==
:::: List of speakers can be found [https://www.microbiota-site.com/microbiota-2019-speakers.html here]
== Registration ==
:::: [https://www.microbiota-site.com/registrations.html Registration and more information] +
8
8th SMRM and Mitochondria-Metabolism Network Meeting, Pune, India, 2020
== General information ==
:::: Flyer available for [https://www.mitoeagle.org/images/b/b2/8th_SMRM_and_Mitochondria-Metabolism_Network_Meeting_Poster.pdf download]
== Venue ==
:::: Indian Institute of Science Education and Research (ISER Pune)
:::: Dr. Homi Bhabha Road
:::: Pashan, Pune 411 008
:::: INDIA
::::[http://www.iiserpune.ac.in/facilities/guesthouse-cum-convention-centre Hotel and Travel]
== Programme ==
:::: [https://indico.tifr.res.in/indico/internalPage.py?pageId=12&confId=7288 here]
== Speakers ==
:::: List of speakers can be found [https://indico.tifr.res.in/indico/internalPage.py?pageId=0&confId=7288 here]
== Organizers ==
:::: The list of organizers can be found [https://indico.tifr.res.in/indico/internalPage.py?pageId=9&confId=7288 here]
== Registration ==
:::: [https://indico.tifr.res.in/indico/internalPage.py?pageId=6&confId=7288 Registration and more information] +
9
9th ÖGMBT Annual Meeting & 8th Life Science Meeting, Innsbruck, Austria +
A
46<sup>th</sup> All India Cell Biology Conference, Navi Mumbai, India, 2024 +
AlgaEurope 2018, Amsterdam, Netherlands, 2018 +
z-Scores were devised to provide a transparent but widely-applicable scoring system for participants in proficiency tests for analytical laboratories. The essential idea is to provide an appropriate scaling of the difference between a participant’s result and the ‘assigned value’ for the concentration of the analyte. Interpretation of a z-score is straightforward but some aspects need careful attention to avoid misconception. Over time several related scores have been devised to cope with a diversified range of applications. The main types of score have recently been codified in ISO 13528 (2015). +
64<sup>th</sup> Annual International Conference of the Associate of Microbiologists of India, Jhansi, India, 2023 +
'''APS Conference: Physiological Bioenergetics: Mitochondria from Bench to Bedside, Bioenergetics17'''. San Diego CA, USA; 2017 August. +
32nd APS Annual Convention, Chicago, USA, 2020 +
AVRO - Association for Research in Vision and Ophthalmology, Honolulu, Hawaii, USA, 2018 +
Joint ASMRM and J-mit Conference, Fukuoka, Japan, 2019 +
9<sup>th</sup> Conference of the Asian Society of Mitochondrial Research and Medicine and 5<sup>th</sup> Conference of Chinese Society of Mitochondrial Research and Medicine (Chinese-Mit), [http://asmrm2012.csp.escience.cn/dct/page/65540 ASMRM 2012], Bejing CN +
10<sup>th</sup> Conference of the Asian Society of Mitochondrial Research and Medicine - [http://asmrm2013.com/common_files/mess.asp ASMRM 2013], Seoul KR +
12<sup>th</sup> Conference of the Asian Society of Mitochondrial Research and Medicine - [http://www.ig.zju.edu.cn/ASMRM/EN/ ASMRM 2015], Hangzhou CN +
[[File:ASMRM2016.jpg|500px|right]]
'''13<sup>th</sup> Conference of the Asian Society of Mitochondrial Research and Medicine and the 16<sup>th</sup> Conference of the Japanese Society of Mitochondrial Research and Medicine (J-mit). The world of mitochondrial diseases: Their diversity and heterogeneity. Shinagawa JP.''' +
'''14<sup>th</sup>Conference of the Asian Society of Mitochondrial Research and Medicine'''. Xi'an, Shaanxi, China; 2017 September. +
15th Conference of the Asian Society of Mitochondrial Research and Medicine, Busan, South Korea, 2018. +
ASMRM 2020, Singapore, SG, 2021 +
ATSPB 2023, Hall in Tirol, Austria, 2023 +
Endurance exercise on a regular basis induces skeletal and cardiac muscle performance adaptation, lower mean arterial blood pressure and metabolic adaptation in a number of organs [1,2]. The latter has been shown to involve mitochondrial biogenesis. Upon injury when training intensity decreases, as well as in aging, these events tend to reverse [2,3]. The aim of the present study was to investigate whether the level of aerobic performance affects mitochondrial respiration in platelets.
Six male and female athletes were subjected to magnetic resonance imaging (MRI) of the heart and blood sampling within three days following an anterior cruciate ligament (ACL) injury. An initial follow-up was performed at the start of rehabilitation training and a late follow up at eight months following injury. The latter exams also included a maximal incremental exercise test with gas analysis. Platelets were isolated by centrifugation and mitochondrial respiration was analyzed using a substrate-uncoupler-inhibitor-protocol.
The total heart volume (THV) was significantly lower following the period of reduced exercise intensity from the time of injury to initial follow-up (p = 0.042, n = 6). There was no significant difference in THV between initial and late follow-up. The maximal ''V''<sub>O2</sub> uptake showed a trend toward increase from initial to late follow-up (p = 0.086, n = 4). There were, however, no significant differences or any discernable trends in respiratory parameters between the time points studied.
In conclusion, there was no difference in platelet mitochondrial respiration in response to alterations in exercise level in this small pilot study. +
[[Image:MITOEAGLE-logo.jpg|left|100px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MITOEAGLE]]
Within a drug discovery program derived from a project for a pharmacological treatment of mitochondrial complex I deficiency, we have developed cell-permeable prodrugs of succinate (NV118) and malonate (NV161) suitable for research use in intact cells. Succinate is an intermediate of the Krebs’ cycle and acts as mitochondrial energy substrate by providing reducing equivalents to complex II (succinate dehydrogenase) of the mitochondrial oxidative phosphorylation pathway. As succinate is converted to malate by complex II, electrons are transferred down the pathway leading to proton pumping and ATP-synthesis. Succinate, as a dicarboxylic acid, is not cell-permeable and for exogenous succinate to enter cells the cell membrane requires permeabilization, using e.g. digitonin or perfringolysin. NV118 allows the researcher to deliver succinate to the cytoplasm without disrupting the plasma membrane. Malonate is a competitive inhibitor of complex II that binds to the active site of succinate dehydrogenase, thus preventing succinate from being metabolized. Like succinate, malonate is a dicarboxylic acid that does not readily permeate through the cell membrane. By using the same prodrug strategy as for NV118, the cell-permeable analogue of malonate, NV161, has been synthesized. NV118 and NV161 are rapidly metabolized, likely by the action of carboxyesterases, releasing succinate and malonate respectively.
Cell-permeable succinate and malonate were tested in a range of human cells and tissues, such as blood cells, fibroblasts, immortalized liver cells and human heart fibers either in the Oroboros O2k-FluoRespirometer (Oroboros Instruments, Innsbruck, Austria) or in the Seahorse Bioscience XFe96 Extracellular Flux Analyser (Seahorse Bioscience, North Billerica, USA). Dose-response curves for both prodrugs were obtained in human complex I inhibited platelets and primary fibroblasts.
NV118 and NV161 dose-dependently support and inhibit succinate-linked mitochondrial respiration in intact human platelets and fibroblasts. NV161 completely inhibits succinate-linked mitochondrial respiration at about ten times lower concentration as compared to malonate. Dimethyl succinate and dimethyl malonate have previously been reported to be cell-permeable, but did not show strong evidence of efficient cell penetration in this study.
We believe that NV118 and NV161 may prove valuable as scientific tools in mitochondrial research, enabling evaluation of complex II in intact cells and tissues. Analogues of both the succinate and malonate series optimized for ''in vivo'' use are simultaneously being developed.
::[http://bioblast.at/images/0/0f/Aasander_Frostner_Poster_MiP2017.pdf '''Poster link''']
[[Image:MITOEAGLE-logo.jpg|left|100px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MitoEAGLE]] +
Primary mitochondrial diseases are a heterogeneous group of rare genetic disorders affecting approximately 125 persons per million. Mutations underlying these diseases give rise to biological changes (including decrease in cellular energy production and increase in reactive oxygen species), leading to organ failure, and commonly early morbidity. Mitochondrial diseases often present in early childhood and lead to the development of severe symptoms, with severe fatigue and myopathy being some of the most prevalent and debilitating clinical signs.
There are currently no cures for mitochondrial diseases, nor any approved pharmaceutical treatments for multisystemic disorders.
Current drug development in mitochondrial diseases focuses mainly on modulation of oxidative stress, regulation of the expression of genes involved in metabolic pathways, modulation of coenzymes, induction of mitochondrial biogenesis, and energy replacement.
In this short review, we present the current landscape of mitochondrial disease drug development, focusing on small molecules in clinical trials conducted by industrial sponsors. +
.-20The-20world-20of-20mitochondrial-20diseases:-20Their-20diversity-20and-20heterogeneity.-20Shinagawa-20JP.-27-27%27){kind=link}
